🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "major milestone" in the fight against drug-resistant strains of the bacteria, according to health experts.

A Worldwide Public Health Issue

Gonorrhoea infections are on the rise globally, with figures suggesting over 82 million new cases each year. Particularly high rates are observed in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune step in the context of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted treatment choices at this time.”

Medical experts are increasingly worried about the rise in treatment-resistant strains. The global health body has designated it as a "critical concern". Ongoing monitoring showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Receive Approval

Zoliflodacin, alternatively called a brand name, was cleared by the US FDA in December for treating gonorrhoea. This STI can lead to major issues, including infertility. Scientists anticipate that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, also received approval in the same week. This medication, which is employed against urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Partnership

This new treatment stemmed from a unique collaborative effort for medication research. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to bring it to fruition.

“This milestone represents a significant shift in the management of superbug gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Outcomes and Worldwide Availability

According to data released by a major medical journal, zoliflodacin eradicated more than 90% of uncomplicated infections. This puts it on an similar efficacy with the typical regimen, which uses a dual-drug approach. The study included hundreds of patients from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the authority to license and sell the drug in many regions with limited resources.

Doctors treating patients have voiced optimism. Access to a single-dose, oral treatment of this kind is hailed as a "critical tool" for gonorrhoea control. This is deemed vital to reduce the burden of the infection for individuals and to halt the transmission of highly drug-resistant gonorrhoea globally.